Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Irish Journal of Medical Science (1971 -)
Published in: Irish Journal of Medical Science (1971 -) 6/2023

03-03-2023 | Gingival Diseases | Original Article

The effect of non-surgical periodontal therapy on salivary IL-6 levels in patients with moderate to severe generalized chronic periodontitis

Authors: Mahvish Khan, Anamika Sharma, Ananya Sharma, Ganesh Singh, Saif Khan, Saheem Ahmad, Ayshah Aysh Ma’an Alrashidi, Subuhi Sherwani, Hemlata Mishra, Ahmad Alsulimani

Published in: Irish Journal of Medical Science (1971 -) | Issue 6/2023

Login to get access

Abstract

Background

Gene regulation of IL-6 is characterized by the presence of inflammatory cytokines, bacterial products, viral infection, and activation of the diacylglycerol-, cyclic AMP-, or Ca + + -activated signal transduction pathways.

Aim

Scaling and root planning (SRP), a non-surgical periodontal therapy, was studied in connection to several clinical parameters for its effect on salivary IL-6 levels in patients with generalized chronic periodontitis.

Methods

For this study, a total of 60 GCP patients were included. Plaque index (PI), gingival index (GI), pocket probing depth (PPD), bleeding on probing percentage (BOP%), and clinical attachment loss were among the clinical indicators covered (CAL).

Results

Following SRP, mean IL-6 levels in patients with GCP were significantly higher in the pre-treatment group (2.93 5.17 pg/ml; p 0.05) than in the posttreatment group (5.78 8.26 pg/ml; baseline). Pre- and post-treatment IL-6 levels for PI (pre), BOP percent (pre/post), GI (post), and PPD were found to be positively correlated (post). In patients with GCP, the study showed a statistically significant correlation between periodontal metrics and salivary IL-6.

Conclusions

Changes in periodontal indices and IL-6 levels that are statistically significant over time indicate that non-surgical treatment is effective, and IL-6 can be regarded as a potent disease activity marker.
Literature
1.
Darveau RP, Tanner A, Page RC (1997) The microbial challenge in periodontitis. Periodontology 2000 14(1):12–32
2.
Bascones Martínez A, Muñoz Corcuera M, Noronha S et al (2009) Host defence mechanisms against bacterial aggression in periodontal disease: Basic mechanisms
3.
Drisko CH (2001) Nonsurgical periodontal therapy. Periodontology 2000, 25(1):77–88
4.
Elter JR, Hinderliter AL, Offenbacher S et al (2006) The effects of periodontal therapy on vascular endothelial function: a pilot trial. Am Heart J 151(1):47-e1CrossRefPubMed
5.
De la Rosa M, Johnston DA, Radike AW (1979) Plaque growth and removal with daily toothbrushing. J Periodontol 50(12):661–664CrossRefPubMed
6.
Polson AM, Goodson JM (1985) Periodontal diagnosis: current status and future needs. J Periodontol 56(1):25–34CrossRefPubMed
7.
8.
Newman MG, Carranza FA, Takei HH, Klokkevold PR (Eds.) (2006) Carranza’s clinical periodontology. Elsevier Brasil
9.
10.
Kishimoto T, Tanaka T, Yoshida K et al (1995) Cytokine signal transduction through a homo-or heterodimer of gp130. Ann N Y Acad Sci 766(1):224–234CrossRefPubMed
11.
Matsuki Y, Yamamoto THARAK, Hara K (1992) Detection of inflammatory cytokine messenger RNA (mRNA)-expressing cells in human inflamed gingiva by combined in situ hybridization and immunohistochemistry. Immunology 76(1):42PubMedPubMedCentral
12.
13.
Hashizume M, Hayakawa N, Mihara M (2008) IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17. Rheumatology (Oxford) 47:1635–1640CrossRefPubMed
14.
Kotake S, Sato K, Kim KJ et al (1996) Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 11:88–95CrossRefPubMed
15.
16.
Naka T, Narazaki M, Hirata M et al (1997) Structure and function of a new STAT-induced STAT inhibitor. Nature 387:924–929CrossRefPubMed
17.
Hirano T, Taga T, Yasukawa K et al (1987) Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci 84:228–231CrossRefPubMedPubMedCentral
18.
19.
Bettelli E, Carrier Y, Gao W et al (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235–238CrossRefPubMed
20.
Hirano T, Matsuda T, Turner M et al (1988) Excessive production of interleukin 6/B cell stimulatory factor‐2 in rheumatoid arthritis. Eur J Immunol 18(11):1797–1802
21.
Yoshizaki K, Matsuda T, Nishimoto N et al (1989) Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood 74:1360–1367CrossRefPubMed
22.
Kawano M, Hirano T, Matsuda T et al (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332:83–85CrossRefPubMed
23.
Nishimoto N, Yoshizaki K, Tagoh H et al (1989) Elevation of serum interleukin 6 prior to acute phase proteins on the inflammation by surgical operation. Clin Immunol Immunopathol 50:399–401CrossRefPubMed
24.
Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Kishimoto T (2005) Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106(8):2627–2632
25.
Savage A, Eaton KA, Moles DR, Needleman I (2009) A systematic review of definitions of periodontitis and methods that have been used to identify this disease. J Clin Periodontol 36:458–467CrossRefPubMed
26.
Tonetti MS, Claffey N (2005) Advances in the progression of periodontitis and proposal of definitions of a periodontitis case and disease progression for use in risk factor research. J Clin Periodontol 32(Suppl 6):210–213CrossRefPubMed
27.
Demmer R, Papapanou PN (2010) Epidemiologic patterns of chronic and aggressive periodontitis- Periodontology 2000
28.
29.
Löe H, Silness J (1963) Periodontal disease in pregnancy I. Prevalence and severity Acta odontologica scandinavica 21(6):533–551CrossRefPubMed
30.
Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S (2011) The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochem Biophys Acta 1813(5):878–888CrossRefPubMed
31.
De Vita F, Romano C, Orditura M et al (2001) Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J Interferon Cytokine Res 21:45–52CrossRefPubMed
32.
Kitamura H, Ohno Y, Toyoshima Y et al (2017) Taketomi A. Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy. Cancer Sci 108:1947–1952.37
33.
Xie WR, Deng H, Li H et al (2006) Robust increase of cutaneous sensitivity, cytokine production and sympathetic sprouting in rats with localized inflammatory irritation of the spinal ganglia. Neuroscience 142:809–822CrossRefPubMed
34.
Haffajee AD, Cugini MA, Dibart S et al (1997) The effect of SRP on the clinical and microbiological parameters of periodontal diseases. J Clin Periodontol 24(5):324–334CrossRefPubMed
35.
Honda T, Domon H, Okui T et al (2006) Balance of inflammatory response in stable gingivitis and progressive periodontitis lesions. Clin Exp Immunol 144(1):35–40CrossRefPubMedPubMedCentral
36.
Jully JM, Béné MC, Martin G, Faure G (1986) Immunohistological identification of cell subsets in human gingival after local treatment for gingivitis or periodontitis. J Clin Periodontol 13(3):223–227CrossRefPubMed
37.
Tonetti MS, D’Aiuto F, Nibali L et al (2007) Treatment of periodontitis and endothelial function. N Engl J Med 356(9):911–920
38.
Marcaccini AM, Meschiari CA, Sorgi CA et al (2009) Circulating interleukin-6 and high-sensitivity C-reactive protein decrease after periodontal therapy in otherwise healthy subjects. J Periodontol 80(4):594–602
39.
Geivelis M, Turner DW, Pederson ED, Lamberts BL (1993) Measurements of interleukin-6 in gingival crevicular fluid from adults with destructive periodontal disease. J Periodontol 64(10):980–983CrossRefPubMed
40.
Goutoudi P, Diza E, Arvanitidou M (2012) Effect of periodontal therapy on crevicular fluid interleukin-6 and interleukin-8 levels in chronic periodontitis. Int J Dent
41.
D’aiuto F, Parkar M, Andreou G et al (2004) Periodontitis and systemic inflammation: control of the local infection is associated with a reduction in serum inflammatory markers. J Dent Res 83(2):156–160
42.
Vidal F, Figueredo CMS, Cordovil I, Fischer RG (2009) Periodontal therapy reduces plasma levels of interleukin-6, C-reactive protein, and fibrinogen in patients with severe periodontitis and refractory arterial hypertension. J Periodontol 80(5):786–791CrossRefPubMed
43.
George AK, Janam P (2013) The short-term effects of non-surgical periodontal therapy on the circulating levels of interleukin-6 and C-reactive protein in patients with chronic periodontitis. J Indian Soc Periodontol 17(1):36CrossRefPubMedPubMedCentral
44.
Shimada Y, Komatsu Y, Ikezawa-Suzuki I et al (2010) The effect of periodontal treatment on serum leptin, interleukin-6, and C-reactive protein. J Periodontol 81(8):1118–1123CrossRefPubMed
45.
Magnusson I, Lindhe J, Yoneyama T, Liljenberg B (1984) Recolonization of a subgingival microbiota following scaling in deep pockets. J Clin Periodontol 11(3):193–207CrossRefPubMed
Metadata
Title
The effect of non-surgical periodontal therapy on salivary IL-6 levels in patients with moderate to severe generalized chronic periodontitis
Authors
Mahvish Khan
Anamika Sharma
Ananya Sharma
Ganesh Singh
Saif Khan
Saheem Ahmad
Ayshah Aysh Ma’an Alrashidi
Subuhi Sherwani
Hemlata Mishra
Ahmad Alsulimani
Publication date
03-03-2023
Publisher
Springer International Publishing
Published in
Irish Journal of Medical Science (1971 -) / Issue 6/2023
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-023-03325-6

Other articles of this Issue 6/2023

Irish Journal of Medical Science (1971 -) 6/2023 Go to the issue

Original Article

Cost awareness amongst irish ophthalmologists

Review Article

International primary hip arthroplasty registry review: findings from current reports

Letter to the Editor

Prolotherapy for knee osteoarthritis: comment on “Demonstrating the effectiveness of Platelet Rich Plasma and Prolotherapy treatments in knee osteoarthritis” by Ceylan et al

Original Article

Serum histone deacetylase 4 longitudinal change for estimating major adverse cardiovascular events in acute coronary syndrome patients receiving percutaneous coronary intervention

Original Article

Two-scale assessment of anxiety and depression in postoperative non-small cell lung cancer patients: their prevalence, risk factors, and prognostic potency

Original Article

Investigation of serum endocan and serglycin levels in obstructive sleep apnea
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits